They are the same molecule with one difference. That difference changes how the body handles it, and it does not make them interchangeable in law.
Ursodeoxycholic acid is one of the better-evidenced compounds in hepatology. It has been used for decades in primary biliary cholangitis and for dissolving cholesterol gallstones, and in the UK it is a prescription-only medicine.
TUDCA is ursodeoxycholic acid with a taurine group attached. That is the entire chemical difference. It is worth understanding what that one modification changes, and what it does not.
Conjugation is a step the liver has to perform
The liver cannot secrete unconjugated bile acids safely. Before UDCA can be sent into the biliary tree, it has to be bound to either glycine or taurine. Conjugation raises water solubility, lowers membrane toxicity, and allows the molecule to be moved across the canalicular membrane by active transport.
So when you take oral UDCA, the taurine conjugate is what your body eventually produces anyway. Taking TUDCA supplies that end product directly.
What unconjugated UDCA meets on the way
Oral UDCA is absorbed passively and incompletely. A portion travels further down the gut, where it is exposed to bacteria carrying bile salt hydrolase enzymes and, further along, to bacterial 7α-dehydroxylation. That pathway converts UDCA into lithocholic acid, the most hydrophobic and cytotoxic bile acid in human physiology. UDCA therapy is known to increase lithocholic acid flux through the large intestine.
One honest caveat here. Taurine conjugates are also substrates for bacterial bile salt hydrolases, so it would be wrong to claim TUDCA is immune to this. What it does have is a different absorption route: it is taken up actively in the terminal ileum by the transporter the body uses for its own conjugated bile salts, which means less of it lingers in the distal gut in the first place.
A crossover study in patients with primary biliary cirrhosis gave oral TUDCA and oral UDCA sequentially at 750 mg per day, with bile acids measured in serum, duodenal bile, urine and faeces by gas chromatography-mass spectrometry.
Biliary enrichment with ursodeoxycholate species reached 32.6% on TUDCA against 29.2% on UDCA. The difference reached statistical significance. It is also 3.4 percentage points, which is modest, and worth reporting as such rather than dressing up.
Setchell KDR, Crosignani A, Podda M, et al. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 1999;29(2):320–327.
Head to head on clinical outcomes
Twenty-three patients with primary biliary cirrhosis took UDCA and TUDCA at 500 mg per day in a crossover design, two six-month periods separated by a three-month washout.
Cholestasis and cytolysis enzymes improved on both compounds compared with baseline. There was no significant difference between them. Both were well tolerated with no reported side effects in either arm.
Larghi A, Crosignani A, Battezzati PM, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Alimentary Pharmacology & Therapeutics 1997;11(2):409–414. PMID: 9146783.
That is the honest summary of the head-to-head evidence: at equivalent doses, in the one direct clinical comparison that exists, TUDCA performed as well as UDCA. Not better. As well.
The line that matters
UDCA is a licensed medicine for diagnosed conditions. TUDCA is sold as a food supplement. Those are different regulatory categories with different evidence requirements behind them, and the chemical relationship between the two molecules does not collapse that distinction.
If a doctor has prescribed UDCA, stay on the UDCA. It is not a compound to be swapped out on the strength of a supplement label.
References
- Setchell KDR, Crosignani A, Podda M, et al. Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology 1999;29(2):320–327.
- Larghi A, Crosignani A, Battezzati PM, et al. Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Alimentary Pharmacology & Therapeutics 1997;11(2):409–414. PMID: 9146783.
Educational and scientific information only. Tauroursodeoxycholic acid (TUDCA) is sold as a food supplement and has not been assessed by the Food Standards Agency, the MHRA, the European Food Safety Authority or the US Food and Drug Administration for preventing, treating or curing any disease. Ursodeoxycholic acid (UDCA) is a prescription-only medicine in the UK. Nothing here is a substitute for prescribed treatment. If you are under medical care or taking prescribed medication, speak to your doctor or pharmacist before starting any supplement.